glp 1 tirzepatide drops Associated with Lower POAG, OHT Risk Compared with Other GLP-1 Drugs GLP-1/GIP Tirzepatide Rx | FancyMeds
Description
This shows that current studies still do not have definitive data in relation to GLP-1 RA medications and risk assessments for clear guidelines in the management of these patients perioperatively
-1775582746855.png&w=3840&q=75)
Until now, the only GLP-1 medications for treating obesity were injectables: semaglutide (Wegovy) and tirzepatide (Zepbound)
Treatment of type 2 diabetes with incretin-based therapies
Limitations Side effects can be more pronounced initially (nausea, diarrhea)
On average, clinical trials show that patients can lose 15-20% of their body weight during treatment
